Ionis Pharmaceuticals, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Ionis Pharmaceuticals, Inc. (IONS) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$168.68 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-09
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$168.68M, a 527.79% decline year-over-year.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $20.80M, a 25.62% decline year-over-year.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$57.09M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $53.46M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $56.60M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$60.05M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$82.85M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$255.73M, a 1520.78% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$168.68M 10-Q · filed 2017-05-09 | -$147.87M derived: sum of 2 quarters · filed 2017-05-09 | -$204.96M derived: sum of 3 quarters · filed 2017-05-09 | -$151.50M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | $20.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$36.29M derived: sum of 2 quarters · filed 2017-03-01 | $17.17M derived: sum of 3 quarters · filed 2017-03-01 | $56.60M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$57.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$3.63M derived: sum of 2 quarters · filed 2016-11-09 | $35.80M 10-Q · filed 2016-11-09 | $63.76M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-06-30 | $53.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $92.89M 10-Q · filed 2016-08-09 | $120.85M derived: sum of 3 quarters · filed 2017-05-09 | $91.57M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-03-31 | $39.43M 10-Q · filed 2017-05-09 | $67.39M derived: sum of 2 quarters · filed 2017-05-09 | $38.11M derived: sum of 3 quarters · filed 2017-05-09 | -$57.27M derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | $27.96M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$1.31M derived: sum of 2 quarters · filed 2017-03-01 | -$96.70M derived: sum of 3 quarters · filed 2017-03-01 | -$60.05M 10-K · filed 2017-03-01 |
| 2015-09-30 | -$29.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$124.67M derived: sum of 2 quarters · filed 2016-11-09 | -$88.02M 10-Q · filed 2016-11-09 | -$138.80M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$95.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$58.74M 10-Q · filed 2016-08-09 | -$109.53M derived: sum of 3 quarters · filed 2017-03-01 | -$134.01M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $36.65M 10-Q · filed 2016-05-05 | -$14.14M derived: sum of 2 quarters · filed 2017-03-01 | -$38.63M derived: sum of 3 quarters · filed 2017-03-01 | -$71.02M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$50.79M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$75.28M derived: sum of 2 quarters · filed 2017-03-01 | -$107.67M derived: sum of 3 quarters · filed 2017-03-01 | -$82.85M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$24.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$56.88M derived: sum of 2 quarters · filed 2015-11-09 | -$32.06M 10-Q · filed 2015-11-09 | -$117.33M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | -$32.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$7.57M 10-Q · filed 2015-08-05 | -$92.84M derived: sum of 3 quarters · filed 2016-02-26 | -$216.15M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $24.82M 10-Q · filed 2015-05-05 | -$60.45M derived: sum of 2 quarters · filed 2016-02-26 | -$183.76M derived: sum of 3 quarters · filed 2016-02-26 | -$215.60M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | -$85.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$208.58M derived: sum of 2 quarters · filed 2016-02-26 | -$240.42M derived: sum of 3 quarters · filed 2016-02-26 | -$255.73M 10-K · filed 2016-02-26 |
| 2013-09-30 | -$123.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$155.15M derived: sum of 2 quarters · filed 2014-11-07 | -$170.46M 10-Q · filed 2014-11-07 | -$165.42M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | -$31.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | -$47.15M 10-Q · filed 2014-08-04 | -$42.11M derived: sum of 3 quarters · filed 2015-03-02 | -$52.72M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | -$15.31M 10-Q · filed 2014-05-06 | -$10.27M derived: sum of 2 quarters · filed 2015-03-02 | -$20.88M derived: sum of 3 quarters · filed 2015-03-02 | $3.21M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$5.57M derived: sum of 2 quarters · filed 2015-03-02 | $18.52M derived: sum of 3 quarters · filed 2015-03-02 | $18.00M 10-K · filed 2015-03-02 |
| 2012-09-30 | -$10.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $13.49M derived: sum of 2 quarters · filed 2013-11-05 | $12.96M 10-Q · filed 2013-11-05 | |
| 2012-06-30 | $24.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $23.57M 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | -$522.00K 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | $108.03M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $23.69M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |